<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02238639</url>
  </required_header>
  <id_info>
    <org_study_id>SLICE 1</org_study_id>
    <nct_id>NCT02238639</nct_id>
  </id_info>
  <brief_title>Pulmonary Embolism as a Cause of COPD Exacerbations</brief_title>
  <acronym>SLICE</acronym>
  <official_title>Efficacy and Safety of an Active Strategy for the Diagnosis and Treatment of Acute Pulmonary Embolism (PE) in Patients With Unexplained Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Chest Physicians</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sociedad Española de Neumología y Cirugía Torácica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Health, Spain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to demonstrate the clinical benefits of an active strategy for the&#xD;
      diagnosis and treatment of PE compared to usual care in patients with unexplained&#xD;
      exacerbations of COPD who require hospital admission.&#xD;
&#xD;
      The secondary objective is to assess the safety of an active strategy for the diagnosis and&#xD;
      treatment of PE compared to usual care in patients with unexplained exacerbations of COPD who&#xD;
      require hospital admission.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality, symptomatic venous thromboembolism recurrence, or need for readmission.</measure>
    <time_frame>90-day follow-up</time_frame>
    <description>Clinical composite endpoint of all-cause mortality, or symptomatic venous thromboembolism recurrence, or need for readmission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>90-day follow-up</time_frame>
    <description>All-cause mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic recurrent venous thromboembolism</measure>
    <time_frame>90-day follow-up</time_frame>
    <description>Symptomatic venous thromboembolic recurrence confirmed by objective testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>90-day follow-up</time_frame>
    <description>Need for readmission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>90-day follow-up</time_frame>
    <description>Major bleeding (defined according to previously published criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant non major bleeding</measure>
    <time_frame>90-day follow-up</time_frame>
    <description>Clinically relevant non major bleeding (defined according to previously published criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>90-day follow-up</time_frame>
    <description>Serious adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">746</enrollment>
  <condition>Pulmonary Embolism</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Active search for pulmonary embolism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All included patients will undergo D-dimer testing. A negative plasma highly sensitive D-dimer value (defined as a D-dimer level below the manufacturers assay threshold) will rule out pulmonary embolism, and no further examination will be performed. For patients with a positive D-dimer value, a multidetector computed tomographic pulmonary angiography (MDCT) will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard management</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All included patients will undergo standard clinical management of their exacerbations, as deemed appropriate by the attending physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).</intervention_name>
    <description>If MDCT is positive for pulmonary embolism, patients will receive anticoagulant treatment according to updated guidelines.&#xD;
If MDCT is negative for pulmonary embolism, patients will receive standard management for their exacerbation.</description>
    <arm_group_label>Active search for pulmonary embolism</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmation of COPD according to SEPAR-ALT criteria: post-bronchodilator forced&#xD;
             expiratory volume in one second (FEV1)/forced vital capacity (FVC) &lt; 0.7;&#xD;
&#xD;
          -  Hospital admission because COPD exacerbation without initial clinical suspicion of PE&#xD;
             in the Emergency Department (according by the Emergency Department physician&#xD;
             evaluation).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to multidetector computed tomographic angiography (allergy to&#xD;
             intravenous contrast medium, or renal failure defined as a creatinine clearance less&#xD;
             than 30 mL/min, according to the Cockcroft-Gault formula)&#xD;
&#xD;
          -  Informed consent denied&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Life expectancy less than 3 months&#xD;
&#xD;
          -  Anticoagulant therapy at the time of hospital admission&#xD;
&#xD;
          -  Diagnosis of pneumothorax, or pneumonia (fever, and purulent sputum, and new&#xD;
             infiltrate in chest X-ray)&#xD;
&#xD;
          -  Diagnosis of lower respiratory tract infection (fever [&gt;37.8ºC], increased sputum&#xD;
             volume and/or increased sputum purulence).&#xD;
&#xD;
          -  Indication of invasive mechanical ventilation at the time of hospital admission;&#xD;
&#xD;
          -  Impossibility for follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Jimenez, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>IRYCIS, Alcala de Henares University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alvar Agusti, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Monreal, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Remedios Otero, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Virgen del Rocio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Galdakao</name>
      <address>
        <city>Baracaldo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Nostra Senyora del Remei</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Capio Sagrat Cor</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cruces</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Coruña</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro</name>
      <address>
        <city>Logroño</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal, IRYCIS, Alcala de Henares University</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Alcorcon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico La Rosaleda</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Txagorritxu</name>
      <address>
        <city>Vitoria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Peces-Barba G, Barberà JA, Agustí A, Casanova C, Casas A, Izquierdo JL, Jardim J, López Varela V, Monsó E, Montemayor T, Viejo JL. [Diagnosis and management of chronic obstructive pulmonary disease: joint guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Latin American Thoracic Society (ALAT)]. Arch Bronconeumol. 2008 May;44(5):271-81. Spanish.</citation>
    <PMID>18448019</PMID>
  </reference>
  <reference>
    <citation>Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55. Epub 2007 May 16. Review.</citation>
    <PMID>17507545</PMID>
  </reference>
  <reference>
    <citation>Camargo CA Jr, Roberts J, Clark S. US emergency department visits for COPD exacerbations between 1992 and 1998. Am J Epidemiol 2001; 153: S80.</citation>
  </reference>
  <reference>
    <citation>Poulsen SH, Noer I, Møller JE, Knudsen TE, Frandsen JL. Clinical outcome of patients with suspected pulmonary embolism. A follow-up study of 588 consecutive patients. J Intern Med. 2001 Aug;250(2):137-43.</citation>
    <PMID>11489063</PMID>
  </reference>
  <reference>
    <citation>Tillie-Leblond I, Marquette CH, Perez T, Scherpereel A, Zanetti C, Tonnel AB, Remy-Jardin M. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med. 2006 Mar 21;144(6):390-6.</citation>
    <PMID>16549851</PMID>
  </reference>
  <reference>
    <citation>Rizkallah J, Man SFP, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2009 Mar;135(3):786-793. doi: 10.1378/chest.08-1516. Epub 2008 Sep 23. Review.</citation>
    <PMID>18812453</PMID>
  </reference>
  <reference>
    <citation>Anderson DR, Kahn SR, Rodger MA, Kovacs MJ, Morris T, Hirsch A, Lang E, Stiell I, Kovacs G, Dreyer J, Dennie C, Cartier Y, Barnes D, Burton E, Pleasance S, Skedgel C, O'Rouke K, Wells PS. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA. 2007 Dec 19;298(23):2743-53. doi: 10.1001/jama.298.23.2743.</citation>
    <PMID>18165667</PMID>
  </reference>
  <reference>
    <citation>Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e419S-e496S. doi: 10.1378/chest.11-2301. Erratum in: Chest. 2012 Dec;142(6):1698-1704.</citation>
    <PMID>22315268</PMID>
  </reference>
  <reference>
    <citation>Pozo-Rodríguez F, López-Campos JL, Alvarez-Martínez CJ, Castro-Acosta A, Agüero R, Hueto J, Hernández-Hernández J, Barrón M, Abraira V, Forte A, Sanchez Nieto JM, Lopez-Gabaldón E, Cosío BG, Agustí A; AUDIPOC Study Group. Clinical audit of COPD patients requiring hospital admissions in Spain: AUDIPOC study. PLoS One. 2012;7(7):e42156. Epub 2012 Jul 31.</citation>
    <PMID>22911875</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 9, 2014</study_first_submitted>
  <study_first_submitted_qc>September 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Health, Spain</investigator_affiliation>
    <investigator_full_name>David Jimenez</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Venous thromboembolism</keyword>
  <keyword>COPD exacerbations</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin fragment D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

